🇺🇸 Emtricitabine/tenofovir disoproxil fumarate in United States
4,638 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 4,638
Most-reported reactions
- Foetal Exposure During Pregnancy — 1,186 reports (25.57%)
- Maternal Exposure During Pregnancy — 1,175 reports (25.33%)
- Abortion Spontaneous — 533 reports (11.49%)
- Osteoporosis — 368 reports (7.93%)
- Drug Ineffective — 304 reports (6.55%)
- Virologic Failure — 265 reports (5.71%)
- Small For Dates Baby — 228 reports (4.92%)
- Caesarean Section — 215 reports (4.64%)
- Death — 195 reports (4.2%)
- Premature Delivery — 169 reports (3.64%)
Other Infectious Disease / Virology approved in United States
Frequently asked questions
Is Emtricitabine/tenofovir disoproxil fumarate approved in United States?
Emtricitabine/tenofovir disoproxil fumarate does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Emtricitabine/tenofovir disoproxil fumarate in United States?
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections is the originator. The local marketing authorisation holder may differ — check the official source linked above.